Novo Nordisk moved to stop two additional late-stage cardiovascular trials of ziltivekimab, citing a data monitoring committee determination that the studies were unlikely to succeed. The pullback follows the earlier failure of the ZEUS trial, where the antibody lowered inflammation markers but did not reduce major clinical events.